Supernus announces positive results from two phase III studies for SPN-812 in ADHD
Supernus announced positive topline results from each of two pivotal Phase III studies of SPN-812 in children for treatment of attention deficit hyperactivity disorder. Both trials were successful in achieving the primary endpoint. December 06, 2018